PARP Inhibitors as a Novel Treatment Strategy for Patients with BRCA-Mutated Metastatic Breast Cancer
Inhibitors of poly(ADP-ribose) polymerase (PARP), such as olaparib and talazoparib, have recently been approved as therapies for BRCA-mutated human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (BC). In addition, olaparib, as well as rucaparib and niraparib, have receiv...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2019-11-01
|
| Series: | European Medical Journal Oncology |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/oncology/article/parp-inhibitors-as-a-novel-treatment-strategy-for-patients-with-brca-mutated-metastatic-breast-cancer/ |